Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 2;27:100553. doi: 10.1016/j.eclinm.2020.100553

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 2 — A-H. Clinical and biological baseline predictors of clinical outcome in SARS-Cov-2^pos patients treated with Sarilumab. A) Baseline IL-6 plasma levels in SARS-Cov-2^pos patients treated with Sarilumab based on clinical improvement at 3 days after Sarilumab treatment, *p = 0.001. B) Baseline PaO₂/FiO₂ in SARS-Cov-2^pos patients treated with Sarilumab based on clinical improvement at 3 days after Sarilumab treatment, *p = 0.004. C) Rate of clinical improvement at 3 days in SARS-Cov-2^pos patients treated with Sarilumab based on baseline IL-6 plasma levels, *p < 0.0001. D) Rate of clinical improvement at 3 days in SARS-Cov-2^pos patients treated with Sarilumab based on baseline PaO₂/FiO₂, p = 0.003. E) Baseline IL-6 plasma levels in SARS-Cov-2^pos patients based on transfer towards ICU within 14 days after Sarilumab treatment, *p = 0.05. F) Baseline PaO₂/FiO₂ in SARS-Cov-2^pos patients based on transfer towards ICU within 14 days after Sarilumab treatment, *p = 0.008. G) Kaplan-Meier analysis of transfer to ICU rate in SARS-Cov-2^pos patients treated with Sarilumab based on pre-treatment IL-6 plasma levels, p = 0.01. H) Kaplan-Meier analysis of transfer to ICU rate in SARS-Cov-2^pos patients treated with Sarilumab based on pre-treatment PaO₂/FiO₂, p = 0.03.